Virbac SA
PAR:VIRP
Virbac SA
Equity Earnings Affiliates
Virbac SA
Equity Earnings Affiliates Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Equity Earnings Affiliates | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Virbac SA
PAR:VIRP
|
Equity Earnings Affiliates
€467k
|
CAGR 3-Years
34%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Sanofi SA
PAR:SAN
|
Equity Earnings Affiliates
€60m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Equity Earnings Affiliates
€500k
|
CAGR 3-Years
8%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-12%
|
|
|
Vetoquinol SA
PAR:VETO
|
Equity Earnings Affiliates
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boiron SA
PAR:BOI
|
Equity Earnings Affiliates
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Medincell SA
PAR:MEDCL
|
Equity Earnings Affiliates
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Virbac SA
Glance View
Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.
See Also
What is Virbac SA's Equity Earnings Affiliates?
Equity Earnings Affiliates
467k
EUR
Based on the financial report for Dec 31, 2024, Virbac SA's Equity Earnings Affiliates amounts to 467k EUR.
What is Virbac SA's Equity Earnings Affiliates growth rate?
Equity Earnings Affiliates CAGR 5Y
20%
Over the last year, the Equity Earnings Affiliates growth was 3%. The average annual Equity Earnings Affiliates growth rates for Virbac SA have been 34% over the past three years , 20% over the past five years .
You don't have any saved screeners yet